MGEN News and Press, Miragen Therapeutics Inc. From 04/29/19

Thinly traded nano cap miRagen Therapeutics (NASDAQ: MGEN ) is up  8%  premarket on light volume in reaction to positive preclinical data on remlarsen, a microRNA-29 replacement, in a rat model of corneal ulceration. The results are being presented today at the Association for Re...

Preclinical data indicate that remlarsen accelerated the healing of corneal injury when compared to placebo miRagen believes the study’s results support that remlarsen may offer a novel therapeutic for prevention of corneal scarring and hazing following injury or ulceration Cornea...

Thinly traded nano cap miRagen Therapeutics (NASDAQ: MGEN ) perks up  19%  premarket, albeit on light volume, on the heels of new interim data from a Phase 1 clinical trial evaluating cobomarsen in adult patients with T-cell leukemia/lymphoma (ATLL). The results were presented at...

Continued evidence of disease stabilization observed in ATLL patients treated with cobomarsen for up to 16 months Cobomarsen allowed for rapid bone marrow recovery following chemotherapy In most patients, biomarkers that have been associated with poor prognosis were reduced following co...

BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, May 8th, at 4:30 p.m. ET to discuss its fina...

Gainers:  Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im...

The following slide deck was published by Miragen Therapeutics, Inc. in conjunction with this Read more ...

miRagen Therapeutics, Inc. (MGEN) Q4 2018 Earnings Conference Call March 13, 2019 04:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors, LLC William Marshall - Co-Founder, President and Chief Executive Officer Jason Leverone - Chief Financial Officer Paul Rubin - Exe...

Miragen Therapeutics (NASDAQ: MGEN ): Q4 GAAP EPS of -$0.33 misses by $0.02 . More news on: Miragen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Cobomarsen tested in clinical trials for three different types of blood cancers Multiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cobomarsen in CTCL Data from four clinical trials of three product candidates expected to be released i...